BERKELEY HEIGHTS, N.J., Dec. 8, 2011 (GLOBE NEWSWIRE) -- Genta Incorporated (OTCBB:GNTA.OB) today announced presentation of results from the Company’s Phase 2b clinical trial using tesetaxel as initial, single-agent chemotherapy in women with advanced breast cancer. The trial is lead by Memorial Sloan-Kettering Cancer Center, New York, NY, in collaboration with three other U.S. based cancer centers. The data are being presented this week at the CTRC-AACR San Antonio Breast Cancer Symposium. Tesetaxel is the leading oral taxane in clinical development.
